SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (Napo) which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, is pleased to announce the appointment of Dr. Dennis M. Fenton, Ph.D., to the Napo Board of Directors. Dr. Fenton has over thirty years of pharmaceutical and biotechnology experience including over 25 years at Amgen, Inc. where he coordinated the design, construction and expansion of manufacturing facilities for Epogen(R) (epoetin alfa) and Neupogen(R) (filgrastim), two of the premier products in the biotechnology industry. Dr. Fenton served in numerous positions at Amgen including executive roles in process development, manufacturing, sales and marketing and research and development, with his last position being Executive Vice President.
